乳腺MRI评估新辅助治疗反应
本文阐述了乳腺MRI在新辅助治疗反应评估中的作用,通过病灶直径、体积和强化变化预测完全缓解、部分缓解或无缓解,并指出纤维化、坏死肿瘤等可导致残留病变高估,非肿块病变、浸润性小叶癌等可导致低估,同时提及扩散加权成像、影像组学和深度学习正在研究中。
要点
- MRI是评估新辅助治疗反应最准确的模态,有助于术前精准规划。
- 纤维化、坏死肿瘤和残留良性肿块可导致残留病变高估。
- 非肿块病变、浸润性小叶癌、激素受体阳性肿瘤等可导致低估。
核心结论
- MRI通过病灶直径、体积和强化变化预测新辅助治疗后的完全缓解、部分缓解或无缓解,但存在高估或低估残留病变的可能。
研究设计与样本
- 本文为综述,基于文献总结乳腺MRI评估新辅助治疗反应的应用、预测指标、误差原因及研究进展。
关键影像表现/征象
- MRI上病灶直径、体积和强化变化用于预测治疗反应。
- 纤维化、坏死肿瘤和残留良性肿块可导致残留病变高估。
- 非肿块病变、浸润性小叶癌、激素受体阳性肿瘤、非同心性缩小模式、抗血管生成治疗和晚期强化灶可导致残留病变低估。
临床应用与阅片要点
- 对已知腋窝淋巴结转移患者,新辅助治疗后可行靶向腋窝清扫以避免腋窝淋巴结清扫相关并发症。
- 阅片时需注意纤维化、坏死肿瘤等可致高估,非肿块病变、浸润性小叶癌等可致低估。
局限性
- MRI可能高估或低估残留病变,影响治疗反应评估准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Neoadjuvant therapy is increasingly being used to treat early-stage triple-negative and human epidermal growth factor 2-overexpressing breast cancers, as well as locally advanced and inflammatory breast cancers. The rationales for neoadjuvant therapy are to shrink tumor size and potentially decrease the extent of surgery, to serve as an in vivo test of response to therapy, and to reveal prognostic information for the patient. MRI is the most accurate modality to demonstrate response to therapy and to help ensure accurate presurgical planning. Changes in lesion diameter, volume, and enhancement are used to predict complete response, partial response, or nonresponse to therapy. However, residual disease may be overestimated or underestimated at MRI. Fibrosis, necrotic tumors, and residual benign masses may be causes of overestimation of residual disease. Nonmass lesions, invasive lobular carcinoma, hormone receptor-positive tumors, nonconcentric shrinkage patterns, the use of antiangiogenic therapy, and late-enhancing foci may be causes of underestimation of residual disease. In patients with known axillary lymph node metastasis, neoadjuvant therapy may be followed by targeted axillary dissection to avoid the potential morbidity associated with an axillary lymph node dissection. Diffusion-weighted imaging, radiomics, machine learning, and deep learning methods are under investigation to improve MRI accuracy in predicting treatment response.©RSNA, 2021.
引用
- Reig B, Lewin AA, Du L, et al. Breast MRI for Evaluation of Response to Neoadjuvant Therapy. Radiographics. 2021. PMID: 33939542. doi:10.1148/rg.2021200134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。